EUCTR2006-001694-23-HU进行中（未招募）不适用
Efficacy of cetuximab in locally advanced or metastatic adenoid cystic carcinoma. Phase II.
ational Institute of Oncology0 个研究点目标入组 50 人开始时间: 2006年5月22日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •age:18-80 year
- •signed informed concent
- •histologically proven adenoid cystic carcinoma
- •EGFR pozitivity
- •overall performance status:ECOG:0-2.
- •suitible cardiac, renal and hepatic function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •bed performance status: ECOG:3-4
- •heart failure (NYHA 2-4), major cardiac arrhytmia
- •creatinin more than 2x UNL, ALT or AST more 5x UNL
研究者
相似试验
已完成
不适用
Study on safety and efficacy of cetuximab in locally advanced, recurrent and/or metastatic oral cancerOral cancerJPRN-UMIN000020218agasaki University300
进行中（未招募）
不适用
Efficacy of cetuximab for preventing progression of CRC liver metastases after selective portal embolisatioEUCTR2007-000973-41-SEKarolinska University Hospital, Huddinge30
进行中（未招募）
1 期
Multimodal therapy (chemotherapy, radiation, surgery) with and without cetuximab, an additional anti-tumor agent, in patients with locally advanced esophageal carcinoma.ocally advanced esophageal carcinoma.MedDRA version: 20.0 Level: LLT Classification code 10041824 Term: Squamous cell carcinoma of esophagus System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10056092 Term: Adenocarcinoma of oesophagus System Organ Class: 100000004864EUCTR2009-016584-10-DESchweizerische Arbeitsgemeinschaft für Klinische Krebsforschung SAKK300
进行中（未招募）
不适用
Multimodal therapy with and without cetuximab in patients with locally advanced esophageal carcinoma. An open-label phase III trialEUCTR2009-016584-10-HUSchweizerische Arbeitsgemeinschaft für Klinische Krebsforschung SAKK300
进行中（未招募）
1 期
Multimodal therapy (chemotherapy, radiation, surgery) with and without cetuximab, an additional anti-tumor agent, in patients with locally advanced esophageal carcinoma.ocally advanced esophageal carcinoma.MedDRA version: 20.0Level: LLTClassification code 10056092Term: Adenocarcinoma of oesophagusSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10041824Term: Squamous cell carcinoma of esophagusSystem Organ Class: 100000004864EUCTR2009-016584-10-ATSchweizerische Arbeitsgemeinschaft für Klinische Krebsforschung SAKK300